{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:00:42Z","timestamp":1790686842071,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination aztreonam\/avibactam is currently under Phase 3 trials for the treatment of serious infections caused by Gram-negative bacteria including those with MBLs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the resistance mechanisms in Enterobacterales exhibiting aztreonam\/avibactam MICs of \u22654\u2009mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Among 8787 Enterobacterales, 17 (0.2%) isolates exhibited an aztreonam\/avibactam MIC of \u22654\u2009mg\/L. Isolates were sequenced and screened for \u03b2-lactamases. Sequences of porins, penicillin-binding protein 3 (PBP3) and expression levels of AmpC and AcrA were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven (11\/4154 isolates; 0.26%) Escherichia coli, three (3\/1981; 0.15%) Klebsiella pneumoniae and three (3\/628; 0.5%) Enterobacter cloacae were identified. All E. coli showed either an \u2018YRIK\u2019 or \u2018YRIN\u2019 insertion in PBP3. In general, these isolates carried blaCMY and\/or blaCTX-M variants, except for one isolate from Korea that also produced NDM-5 and one isolate from Turkey that produced OXA-48. Two DHA-1-producing K. pneumoniae overexpressed acrA and had a premature stop codon in either OmpK35 or OmpK36, whereas a third K. pneumoniae carried blaPER-2 and had a premature stop codon in OmpK35. All three E. cloacae expressed AmpC at levels \u2265570-fold, but sequence analysis did not reveal known amino acid alterations associated with decreased avibactam binding or increased hydrolysis of \u03b2-lactams. Minor amino acid polymorphisms within OmpC, OmpF and PBP3 were noted among the E. cloacae.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A small number of isolates (0.2%) met the inclusion criteria. E. coli showed altered PBP3 as the most relevant resistance mechanism, whereas K. pneumoniae had multiple resistance mechanisms. Further investigations are needed to clarify resistance in E. cloacae.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab279","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:08:50Z","timestamp":1627038530000},"page":"2833-2838","source":"Crossref","is-referenced-by-count":46,"title":["Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019"],"prefix":"10.1093","volume":"76","author":[{"given":"Rodrigo E","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B","family":"Doyle","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis F","family":"Arhin","sequence":"additional","affiliation":[{"name":"Pfizer, Inc, Kirkland, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"2021101808542694400_dkab279-B1","year":"2019"},{"key":"2021101808542694400_dkab279-B2","year":"2019"},{"key":"2021101808542694400_dkab279-B3"},{"key":"2021101808542694400_dkab279-B4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021101808542694400_dkab279-B5","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"2021101808542694400_dkab279-B6","doi-asserted-by":"crossref","first-page":"e02243-16","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dkaa504","article-title":"Aztreonam\/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019","volume":"76","author":"Sader","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2021101808542694400_dkab279-B8","year":"2018"},{"key":"2021101808542694400_dkab279-B9","year":"2020"},{"key":"2021101808542694400_dkab279-B10","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/ofid\/ofz004","article-title":"Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: analysis of the distribution of \u03b2-lactamase resistance genes and lineage background in the United States","volume":"6","author":"Mendes","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021101808542694400_dkab279-B11","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1128\/AAC.03930-14","article-title":"Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel \u03b2-lactamases, GES-22 and VIM-35","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021101808542694400_dkab279-B13","doi-asserted-by":"crossref","first-page":"e01659-20","DOI":"10.1128\/AAC.01659-20","article-title":"Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-\u03b2-lactamase-producing Escherichia coli isolates","volume":"64","author":"Sadek","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B14","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkaa021","article-title":"High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam\/avibactam","volume":"75","author":"Periasamy","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021101808542694400_dkab279-B15","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B16","doi-asserted-by":"crossref","first-page":"e02476-16","DOI":"10.1128\/AAC.02476-16","article-title":"Exploring the landscape of diazabicyclooctane (DBO) inhibition: avibactam inactivation of PER-2 \u03b2-lactamase","volume":"61","author":"Ruggiero","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808542694400_dkab279-B18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fmicb.2018.01422","article-title":"Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in Klebsiella pneumoniae","volume":"9","author":"Nicolas-Chanoine","year":"2018","journal-title":"Front Microbiol"},{"key":"2021101808542694400_dkab279-B19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dkaa391","article-title":"Activity of \u03b2-lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2021101808542694400_dkab279-B20","doi-asserted-by":"crossref","first-page":"e97202","DOI":"10.1371\/journal.pone.0097202","article-title":"Resistance to \u03b2-lactam antibiotics conferred by point mutations in penicillin-binding proteins PBP3, PBP4 and PBP6 in Salmonella enterica","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2833\/40641253\/dkab279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2833\/40641253\/dkab279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:21:47Z","timestamp":1634761307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/2833\/6357869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,26]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab279","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,26]]}}}